Skip to content

Long term effect of Japanese Kampo formula gosyajinkigan in diabetic complication; randomized open-labeled trial.

Long term effect of Japanese Kampo formula gosyajinkigan in diabetic complication; randomized open-labeled trial. - Long term effect of Japanese Kampo formula gosyajinkigan in diabetic complication; randomized open-labeled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000010598
Enrollment
1500
Registered
2013-05-01
Start date
2000-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

Regular treatment plus Kampo formulation goshajinkigan (TJ107) every 3 preprandial for 5 years Regular treatment

Sponsors

Keio University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: volunteers who had type 2 diabetes mellitus and a glycated hemoglobin level of 6.5% or more and who either were between the ages of 40 and 75 years without neither macroalbuminuria nor serum creatinin level of more than 1.3 mg per deciliter nor diabetic retinopathy over pre-proliferative retinopathy.

Exclusion criteria

Exclusion criteria: past macrovascular event including stroke, myocardial infarction, angina pectoris, foot gangrene, atheroscrerotic obstruction and other serious complication, taking other kampo formulation, drug allergy to TJ107, pregnant or lactating women and unwillingness to enter the study. Additional exclusion criteria were a body mass index of ≥30 kg/m2; 2 or more digestive system symptoms (e.g., gastrointestinal weakness, anorexia, nausea, and diarrhea); and 3 or more symptoms or activities indicative of sensitivity to heat, including a preference for dressing lightly, sweating upwards from the neck, a liking for cold water, a flushed face, congestion of the eyeballs, and a tendency towards high body temperatures (not less than 36.7 degrees cercius).

Design outcomes

Primary

MeasureTime frame
The prespecified primary endpoints were the first occurrence of nonfatal myocardial infarction or nonfatal stroke or one or more upstaging of diabetic nephropathy(DN) or retinopathy(DR).

Secondary

MeasureTime frame
body weight, blood pressure, fasting blood glucose, glycated hemoglobin, serum insulin (c-peptide reactivity on insulin user) , total cholesterol, triglycelide, high density lipoprotein, serum creatinin, urea nitrogen and diabetic neuropathy

Countries

Japan

Contacts

Public ContactKenji Watanabe

School of medicine, Keio University centor for Kampo medicine

watanabekenji@a6.keio.jp03-5366-3824

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026